A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Recruiting

Phase 3

Remibrutinib vs. DupilumabA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Sponsor:

Novartis Pharmaceuticals

Code:

NCT06868212

Conditions

Chronic Spontaneous Urticaria (CSU)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Remibrutinib matching placebo

Dupilumab

Placebo solution for injection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-29. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2025-10-31.